Synopsys — 7.8/10 — $395.95

Synopsys is the global leader in Electronic Design Automation (EDA), providing software, IP, and hardware used to design and verify semiconductor chips. The company operates within a Synopsys/Cadence duopoly (~65% combined EDA market share) -- a textbook oligopoly where switching costs are enormous and chip design literally cannot happen without EDA tools. Following the July 2025 close of its $35B acquisition of Ansys, Synopsys has expanded into multiphysics simulation and analysis, repositioning as a silicon-to-systems engineering solutions leader. CEO Sassine Ghazi (Dec 2023) leads alongside Executive Chairman Aart de Geus (co-founder, CEO 1986-2023). FY ends October; latest quarter is FY2026Q1 (calendar Q4 2025).

The business model is among the strongest in enterprise software. 84% recurring revenue, $11.3B backlog providing ~1.2x forward revenue visibility, virtually 100% of advanced-node tape-outs (2nm and below) using SNPS tools, and a TAM that just doubled from ~$15B to ~$31B with the Ansys acquisition. Every AI accelerator, GPU, TPU, and custom ASIC requires EDA tools -- making Synopsys a direct beneficiary of the AI chip design explosion.

The stock is de-rated on acquisition integration noise and IP execution concerns. At ~27.5x FY2026E EPS ($14.40), multiples have compressed meaningfully from the 40x+ levels seen in 2024. The IP business is in a transitional year with margin compression from ~35%+ to ~16%. China revenue (ex-Ansys) has declined due to cumulative export restrictions. However, the underlying oligopoly structure, AI tailwinds, and Ansys TAM expansion remain among the strongest competitive moats in technology.

SNPS receives a composite score of 7.8/10, reflecting a high-quality compounder temporarily de-rated on acquisition integration noise and IP execution concerns. The underlying business model (EDA duopoly + AI secular growth + Ansys TAM expansion) remains among the strongest in technology.

Bull case: SNPS is an irreplaceable oligopoly beneficiary of the AI chip design explosion. Ansys integration expands TAM 2x and enables silicon-to-systems differentiation. Agentic AI for EDA could unlock a paradigm shift in pricing models. At ~27.5x FY2026E EPS -- a meaningful discount to historical multiples -- the risk/reward skews favorably for a business with 80%+ recurring revenue, $11.3B backlog, and secular growth drivers.

Bear case: IP business execution stumbles and the transitional year could extend. $10B debt from Ansys weighs on financial flexibility. China restrictions are cumulative and accelerating. Organic EDA growth (~8-9%) is below long-term targets. Integration of a $35B acquisition always carries execution risk.

Bottom line: The 78/100 score reflects excellent quality gated by near-term execution risk on IP and early-stage Ansys integration. The oligopoly structure, 80%+ recurring revenue, and expanding TAM ($31B) support a premium multiple over time.

Key catalysts and monitoring points:

• Ansys revenue synergies: First joint solutions expected 1H 2026 with monetization targeted FY2027. $400M revenue synergy run rate by year 4 is the key benchmark.
• Cost synergy execution: $400M run rate by year 3, with 10% workforce reduction largely complete. Track quarterly margin progression.
• IP business recovery: Management expects HPC title delays closed by mid-FY2026 with recovery back-half weighted, particularly Q4. Watch Design IP margins toward ~35%.
• Organic EDA growth: ~8-9% currently vs 12% long-term target. Acceleration toward double digits would signal structural improvement.
• China revenue trajectory: ~8.8% of revenue (incl. Ansys). Monitor impact of cumulative export restrictions and domestic competitor gains.
• Agentic AI monetization: L1-L5 autonomy roadmap for chip design. Watch for value-based or token-based pricing model announcements.
• NVIDIA partnership outcomes: $2B investment for GPU-accelerated EDA and Omniverse digital twins. Track commercial traction.
• Debt reduction: $10B total from Ansys, $4.3B term loans already repaid by FY26Q1. Watch FCF allocation toward further deleveraging.

For the full analysis, see the Business Model, Financials, and Valuation pages.

Concerns, Catalysts & Risks -- full analysis

Hold at current levels -- Synopsys is a world-class oligopoly with the deepest moat in enterprise software, temporarily de-rated on acquisition noise and a transitional IP business. At $395.95 (~37% below the all-time high, near the bottom of the 52-week range of ~$360-$630), the stock reflects meaningful pessimism for a business of this quality.

The setup favors patient holders. The EDA duopoly is irreplaceable -- no chip can be designed without these tools, switching costs span years, and AI chip complexity is accelerating demand. The Ansys acquisition doubles the addressable market and creates a unique silicon-to-systems platform. At ~27.5x FY2026E EPS, the valuation has compressed materially from the 40x+ levels of 2024, offering a more attractive entry for a business with 80%+ recurring revenue and secular tailwinds.

What would upgrade the recommendation to BUY: (1) Evidence of IP business recovery with margins returning toward 30%+ in 2H FY2026. (2) Organic EDA growth accelerating toward the 12% long-term target. (3) Ansys revenue synergies becoming quantifiable in FY2027 guidance. (4) Further debt reduction bringing leverage to more comfortable levels. Two or three of these catalysts materializing in the next 2-3 quarters would warrant upgrading from HOLD to BUY.